Pharmacoeconomic review report Dexamethasone (Ozurdex) (Allergan Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Cost effectiveness.

Physical Description:

1 online resource (38 pages)

Other Title:

Pharmacoeconomic review report Dexamethasone

Place of Publication:

Ottawa (ON) : CADTH, 2018.

Summary:

Dexamethasone intravitreal implant (Ozurdex) is a glucocorticoid receptor agonist that targets angiogenic vascular-endothelial growth factor (VEGF) and pro-inflammatory pathways of diabetic macular edema (DME). It received a Health Canada notice of compliance on April 16, 2015 for the treatment of DME in adult patients who are pseudophakic. Dexamethasone implant is available as a 700 mcg intravitreal injection to be administered per eye -- re-administered when there is presence of macular edema. The price is 1,400 per single-use 700 mcg intravitreal implant. The manufacturer requested reimbursement for the Health Canada-indicated population. CADTH previously recommended that dexamethasone implant not be reimbursed for the treatment of macular edema following central retinal vein occlusion due to uncertainty in the duration of treatment effect which resulted in uncertainty in the cost-effectiveness of dexamethasone implant compared with sham treatment. The manufacturer submitted a cost-utility analysis of dexamethasone implant compared with a "watch and wait" (no active treatment) approach for the Health Canada indication of adults with DME who are pseudophakic from the public-payer perspective over a 15-year time horizon.

Notes:

Description based on publisher supplied metadata and other sources.